These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22285716)

  • 1. Serotonin 2A receptor, serotonin transporter and dopamine transporter alterations in dogs with compulsive behaviour as a promising model for human obsessive-compulsive disorder.
    Vermeire S; Audenaert K; De Meester R; Vandermeulen E; Waelbers T; De Spiegeleer B; Eersels J; Dobbeleir A; Peremans K
    Psychiatry Res; 2012 Jan; 201(1):78-87. PubMed ID: 22285716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder.
    Hesse S; Müller U; Lincke T; Barthel H; Villmann T; Angermeyer MC; Sabri O; Stengler-Wenzke K
    Psychiatry Res; 2005 Oct; 140(1):63-72. PubMed ID: 16213689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder.
    Perani D; Garibotto V; Gorini A; Moresco RM; Henin M; Panzacchi A; Matarrese M; Carpinelli A; Bellodi L; Fazio F
    Neuroimage; 2008 Aug; 42(1):306-14. PubMed ID: 18511303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT.
    van der Wee NJ; Stevens H; Hardeman JA; Mandl RC; Denys DA; van Megen HJ; Kahn RS; Westenberg HM
    Am J Psychiatry; 2004 Dec; 161(12):2201-6. PubMed ID: 15569890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin transporter and dopamine transporter imaging in the canine brain.
    Peremans K; Goethals I; De Vos F; Dobbeleir A; Ham H; Van Bree H; Van Heeringen C; Audenaert K
    Nucl Med Biol; 2006 Oct; 33(7):907-13. PubMed ID: 17045171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder.
    Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Wenzel T; Zettinig G; Hornik K; Pirker W; Thau K
    Neuropsychopharmacology; 2008 Dec; 33(13):3126-34. PubMed ID: 18354388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers.
    Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Schmidl-Mohl B; Wenzel T; Demal U; Zettinig G; Hornik K; Thau K
    Neuropsychopharmacology; 2007 Aug; 32(8):1661-8. PubMed ID: 17192774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder.
    Pogarell O; Tatsch K; Juckel G; Hamann C; Mulert C; Pöpperl G; Folkerts M; Choukèr M; Riedel M; Zaudig M; Möller HJ; Hegerl U
    Neuropsychopharmacology; 2004 Oct; 29(10):1910-7. PubMed ID: 15292904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD).
    Stengler-Wenzke K; Müller U; Angermeyer MC; Sabri O; Hesse S
    Eur Arch Psychiatry Clin Neurosci; 2004 Aug; 254(4):252-5. PubMed ID: 15309396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder.
    Hesse S; Stengler K; Regenthal R; Patt M; Becker GA; Franke A; Knüpfer H; Meyer PM; Luthardt J; Jahn I; Lobsien D; Heinke W; Brust P; Hegerl U; Sabri O
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):606-17. PubMed ID: 21232166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study.
    Matsumoto R; Ichise M; Ito H; Ando T; Takahashi H; Ikoma Y; Kosaka J; Arakawa R; Fujimura Y; Ota M; Takano A; Fukui K; Nakayama K; Suhara T
    Neuroimage; 2010 Jan; 49(1):121-6. PubMed ID: 19660554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder.
    Kim CH; Koo MS; Cheon KA; Ryu YH; Lee JD; Lee HS
    Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1637-43. PubMed ID: 14513291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W; Brand L; Stein DJ; Harvey BH
    Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder.
    Pogarell O; Hamann C; Pöpperl G; Juckel G; Choukèr M; Zaudig M; Riedel M; Möller HJ; Hegerl U; Tatsch K
    Biol Psychiatry; 2003 Dec; 54(12):1406-13. PubMed ID: 14675805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD).
    Pogarell O; Poepperl G; Mulert C; Hamann C; Sadowsky N; Riedel M; Moeller HJ; Hegerl U; Tatsch K
    Eur Neuropsychopharmacol; 2005 Oct; 15(5):521-4. PubMed ID: 16139170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder.
    Hasselbalch SG; Hansen ES; Jakobsen TB; Pinborg LH; Lønborg JH; Bolwig TG
    Acta Psychiatr Scand; 2007 May; 115(5):388-94. PubMed ID: 17430417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.
    Stengler-Wenzke K; Müller U; Barthel H; Angermeyer MC; Sabri O; Hesse S
    Neuropsychobiology; 2006; 53(1):40-5. PubMed ID: 16397403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuro-imaging the serotonin 2A receptor as a valid biomarker for canine behavioural disorders.
    Vermeire S; Audenaert K; De Meester R; Vandermeulen E; Waelbers T; De Spiegeleer B; Eersels J; Dobbeleir A; Peremans K
    Res Vet Sci; 2011 Dec; 91(3):465-72. PubMed ID: 21051063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
    Kim E; Howes OD; Park JW; Kim SN; Shin SA; Kim BH; Turkheimer FE; Lee YS; Kwon JS
    Psychol Med; 2016 Jan; 46(2):357-66. PubMed ID: 26423910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
    Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.